NCT07088146

Dexamethasone in Prolonging the Duration of Spinal Anesthesia Among Pregnant Patients

Role of Intravenous Dexamethasone in Prolonging the Duration of Sub-Arachnoid Block in Pregnant Patients Undergoing Lower Segment Cesarean Section

• Status: Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 110 (estimated)
• Sponsor: Rawalpindi Medical College · Academic / Other
• Sex: Female
• Age: 16 Years – 40 Years
• Healthy volunteers: Accepted

Summary

Lower segment C section is one of the most commonly performed surgeries worldwide. It is performed in spinal anesthesia. During Spinal Anesthesia a local anesthetic drug is administered in a space surrounding spinal cord and it blocks nerves originating from spinal cord providing both anesthesia and analgesia. This technique avoids harmful exposure of drugs to the baby inside the womb of mother. However this technique provides anesthesia and analgesia of limited duration which can be prolonged by addition of drugs to patient management regimen. One such drug is Dexamethasone which is a steroid commonly administered in the peri-operative period.

Detailed description

To prolong the duration of Sub-Arachnoid block number of drugs which are known as adjuvants can be used. One of the commonly used adjuvant is Dexamethasone a steroid given by intravenous route having anti-emetic and anti-inflammatory effect. This drug also prolongs the duration of Sub-Arachnoid block which can be helpful in case of lengthy surgical procedure and also extends the duration of analgesia in the post operative period.

Conditions

• Spinal Anesthesia
• Post Operative Analgesia

Interventions

Type	Name	Description
DRUG	Dexamethasone	Immediately after sub-arachnoid block 8mg of Dexamethasone will be administered intravenously
DRUG	Placebo	2ml of Normal saline will be given intravenously immediately after administration of spinal anesthesia

Timeline

• Start date: 2025-07-20
• Primary completion: 2025-10-20
• Completion: 2025-10-20
• First posted: 2025-07-28
• Last updated: 2025-07-28

Locations

1 site across 1 country: Pakistan

Regulatory

• FDA-regulated drug study